Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

摘要: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a debilitating autoimmune neuropathy that treated with intravenous immunoglobulin (IVIG). The aim of this retrospective study was to investigate the efficacy and safety sucrose-free IVIG Octagam® (Octapharma AG, Lachen, Switzerland) in patients CIDP. Data from 47 who received at least one dose Octagam were collected records 11 centres France. Efficacy assessed using Overall Neuropathy Limitation Scale (ONLS). Safety evaluated adverse event rates. 24 naive (n = 11) or had stopped IVIG ≥ 12 weeks before   initiation therapy (washout group; n  = 13) included analysis. At 4 months post-initiation treatment, 41.7% improved their functional status (decrease of ≥ 1 ONLS score) significant change   in score baseline (– 0.42; p = 0.04; signed test). Functional reduced only two patients: patient IVIG-naive group IVIG-washout group. All analysis, which showed well tolerated, frequency 0.04 events per course. most common drug reaction headache. These real-life results are consistent reported randomised controlled studies. A long-term prospective CIDP warranted. Octapharma, France SAS.